Therefore, sleep changes in individuals at preclinical stages of AD might correlate with early tau brainstem pathology, and as a sort of “canary in a coal mine,” sleep disturbances might be an early AD biomarker (Iranzo et al., 2009; Bombois et al., 2010). Here, MAPT is linked to Alzheimer disease.